TJ Chao, MPAS, PA-C

TJ Chao, MPAS, PA-C, discusses how treatment goals for prurigo nodularis should be based on disease severity and comorbidities, with adjustments to the treatment approach to optimize patient outcomes.

TJ Chao, MPAS, PA-C, discusses how the recently approved systemic biologic treatments for prurigo nodularis (PN), dupilumab and nemolizumab, differ in their mechanisms of action, efficacy, safety profiles, and how they compare to other treatment options for PN.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Clinicians analyze long-term efficacy data in psoriasis treatments, focusing on how they communicate and contextualize information about treatment duration to their patients.

Physicians examine the enduring effectiveness and key findings from the POETYK PSO-1 clinical trials, evaluating their impact on the evolving landscape of psoriasis treatment options.

Medical experts explore approaches for addressing suboptimal outcomes in systemic psoriasis treatments, including methods to enhance therapeutic efficacy and criteria for transitioning to alternative treatments.

Dermatology experts examine the role of IL-17 inhibitors in psoriasis management, focusing on treatment strategies, swift clinical responses, and their effectiveness across various anatomical sites affected by plaque psoriasis.

Medical professionals discuss ongoing clinical trials and novel medications for the treatment of psoriasis.

Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Key opinion leaders explore the management of plaque psoriasis, addressing treatment-related challenges and emphasizing the importance of effective communication for informed decision-making in therapy selection.

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Medical experts specializing in plaque psoriasis offer a comprehensive overview of the current treatment landscape, its evolution, and the disease's psychological and physical impacts.

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies. Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. Additionally, the discussion explores strategies for communicating treatment mechanisms to patients and fostering collaborative engagement in the treatment selection process.

TJ Chao, MPAS, PA-C, examines the case of an 18-year-old female with persistent AD, wherein the patient attributes her flares to her housing conditions. He discusses her treatment plan and addresses the challenges posed by red face syndrome induced by dupilumab, while commenting on how the panel managed patient expectations, treatment preferences, and sustained disease control.

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

Experts in dermatology share their insights on how to approach corticosteroid hesitancy in their dermatology patient populations.

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C comment on the practical aspects of utilizing topical corticosteroids, including potency, formulation, administration, and utility.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.

Experts discuss key takeaways for providers in the management of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss possible treatment algorithms when using tapinarof for plaque psoriasis (PP) patients.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss the clinical importance of the remittive effect in plaque psoriasis (PP) patients.